HIGHLIGHTS
- who: Yue Zhao from the Nanjing Drum Tower Hospital, China Emory University, United States have published the Article: Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients, in the Journal: (JOURNAL)
- what: Based on the studies of CheckMate-649 and ATTRACTION-4 for significantly improved progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), an anti-PD-1 antibody of nivolumab combined with chemotherapy has been recommended as the first-line treatment for AGC .
- how: The enumeration data were compared by the c2 test . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.